Regulus Therapeutics reported $-7551000 in Pre-Tax Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Alnylam Pharmaceuticals ALNY:US USD -329357000 54.68M
AstraZeneca AZN:LN USD 3.09B 52M
Biogen BIIB:US USD 821M 53.8M
Celldex Therapeutics CLDX:US USD -26784000 546K
Gilead Sciences GILD:US USD 2.52B 357M
GlaxoSmithKline GSK:LN GBP 1.36B 1.07B
Intercept Pharmaceuticals ICPT:US USD -104087000 83.77M
Intrexon XON:US USD -7694000 18.45M
Merk MRK:US USD 4.89B 560M
Omeros OMER:US USD -54792000 13.1M
Regulus Therapeutics RGLS:US USD -7551000 293K
Sangamo Biosciences SGMO:US USD -53125000 10.03M
Spectrum Pharmaceuticals SPPI:US USD -21913000 7.12M
Takeda 4502:JP JPY 107.15B 42.6B
Vital Therapies VTL:US USD -21224000 677K
YTE INCY:US USD 178.22M 131.36M